SUPPLEMENT
Q2 2025 — Financial disclosures
Q2 2025PDF · 10 pages541 KB
Merck & Co., Inc., Rahway, N.J., USA Financial Highlights Package Second Quarter 2025 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 2Q25 and June YTD 25.......3 Table 2b: GAAP to Non-GAAP Reconciliation 2Q24 and June YTD 24.......4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / International 2Q25.................................................6 Table 3b: Sales – U.S. / International June YTD 25.....................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense .............................................................9 -- 1 of 10 -- Sales 15,529 $ 15,806 $ 31,335 $ 15,775 $ 16,112 $ 31,887 $ 16,657 $ 15,624 $ 64,168 $ -2% -2% Costs, Expenses and Other Cost of sales 3,419 3,557 6,976 3,540 3,745 7,285 4,080 3,828 15,193 -5% -4% Selling, general and administrative 2,552 2,649 5,202 2,483 2,739 5,221 2,731 2,864 10,816 -3% 0% Research and development 3,621 4,048 7,669 3,992 3,500 7,492 5,862 4,585 17,938 16% 2% Restructuring costs 69 560 629 123 80 202 56 51 309 * * Other (income) expense, net (35) (7) (43) (33) 42 12 (162) 126 (24) * * Income Before Taxes 5,903 4,999 10,902 5,670 6,006 11,675 4,090 4,170 19,936 -17% -7% Income Tax Provision 818 571 1,388 903 545 1,447 929 425 2,803 Net Income 5,085 4,428 9,514 4,767 5,461 10,228 3,161 3,745 17,133 -19% -7% Less: Net Income Attributable to Noncontrolling Interests 6 1 8 5 6 11 4 2 16 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,079 $ 4,427 $ 9,506 $ 4,762 $ 5,455 $ 10,217 $ 3,157 $ 3,743 $ 17,117 $ -19% -7% Earnings per Common Share Assuming Dilution 2.01 $ 1.76 $ 3.77 $ 1.87 $ 2.14 $ 4.02 $ 1.24 $ 1.48 $ 6.74 $ -18% -6% Average Shares Outstanding Assuming Dilution 2,531 2,513 2,522 2,544 2,544 2,544 2,541 2,537 2,541 Tax Rate 13.9% 11.4% 12.7% 15.9% 9.1% 12.4% 22.7% 10.2% 14.1% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 2Q June YTD % Change MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a Full Year 2025 2Q 1Q 1Q 2Q 3Q 2024 June YTD June YTD 4Q -- 2 of 10 -- Sales 15,806 $ 16,112 $ -2% 31,335 $ 31,887 $ -2% Costs, Expenses and Other Cost of sales 3,557 3,745 -5% 6,976 7,285 -4% Selling, general and administrative 2,649 2,739 -3% 5,202 5,221 0% Research and development 4,048 3,500 16% 7,669 7,492 2% Restructuring costs 560 80 * 629 202 * Other (income) expense, net (7) 42 * (43) 12 * Income Before Taxes 4,999 6,006 -17% 10,902 11,675 -7% Income Tax Provision 571 545 1,388 1,447 Net Income 4,428 5,461 -19% 9,514 10,228 -7% Less: Net Income Attributable to Noncontrolling Interests 1 6 8 11 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 4,427 $ 5,455 $ -19% 9,506 $ 10,217 $ -7% Earnings per Common Share Assuming Dilution 1.76 $ 2.14 $ -18% 3.77 $ 4.02 $ -6% Average Shares Outstanding Assuming Dilution 2,513 2,544 2,522 2,544 Tax Rate 11.4% 9.1% 12.7% 12.4% * 100% or greater GAAP % Change June YTD 2025 June YTD 2024 MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change 2Q25 2Q24 -- 3 of 10 -- Second Quarter Cost of sales 3,557 $ 576 165 741 2,816 $ Selling, general and administrative 2,649 15 1 16 2,633 Research and development 4,048 3 53 56 3,992 Restructuring costs 560 560 560 – Other (income) expense, net (7) (61) (61) 54 Income Before Taxes 4,999 (594) (779) 61 (1,312) 6,311 Income Tax Provision (Benefit) 571 (102) (3) (139) (3) 14 (3) (146) (4) (373) 944 Net Income 4,428 (492) (640) 47 146 (939) 5,367 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 4,427 (492) (640) 47 146 (939) 5,366 Earnings per Common Share Assuming Dilution 1.76 $ (0.20) (0.25) 0.02 0.06 (0.37) 2.13 $ Tax Rate 11.4% 15.0% June YTD Cost of sales 6,976 $ 1,196 201 1,397 5,579 $ Selling, general and administrative 5,202 38 1 39 5,163 Research and development 7,669 10 53 63 7,606 Restructuring costs 629 629 629 – Other (income) expense, net (43) (3) (168) (171) 128 Income Before Taxes 10,902 (1,241) (884) 168 (1,957) 12,859 Income Tax Provision (Benefit) 1,388 (219) (3) (157) (3) 36 (3) (146) (4) (486) 1,874 Net Income 9,514 (1,022) (727) 132 146 (1,471) 10,985 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 9,506 (1,022) (727) 132 146 (1,471) 10,977 Earnings per Common Share Assuming Dilution 3.77 $ (0.40) (0.29) 0.05 0.06 (0.58) 4.35 $ Tax Rate 12.7% 14.6% Only the line items that are affected by non-GAAP adjustments are shown. (4) Represents tax benefits primarily resulting from favorable audit adjustments. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. MERCK & CO., INC., RAHWAY, N.J., USA THREE AND SIX MONTHS ENDED JUNE 30, 2025 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a GAAP Acquisition- and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP Certain Other Items -- 4 of 10 -- Second Quarter Cost of sales 3,745 $ 606 66 672 3,073 $ Selling, general and administrative 2,739 24 31 55 2,684 Research and development 3,500 20 20 3,480 Restructuring costs 80 80 80 – Other (income) expense, net 42 (17) (49) (66) 108 Income Before Taxes 6,006 (633) (177) 49 (761) 6,767 Income Tax Provision (Benefit) 545 (129) (3) (30) (3) 11 (3) (259) (4) (407) 952 Net Income 5,461 (504) (147) 38 259 (354) 5,815 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 5,455 (504) (147) 38 259 (354) 5,809 Earnings per Common Share Assuming Dilution 2.14 $ (0.20) (0.06) 0.02 0.10 (0.14) 2.28 $ Tax Rate 9.1% 14.1% June YTD Cost of sales 7,285 $ 1,069 182 1,251 6,034 $ Selling, general and administrative 5,221 45 36 81 5,140 Research and development 7,492 36 2 38 7,454 Restructuring costs 202 202 202 – Other (income) expense, net 12 (21) (165) (186) 198 Income Before Taxes 11,675 (1,129) (422) 165 (1,386) 13,061 Income Tax Provision (Benefit) 1,447 (221) (3) (72) (3) 36 (3) (259) (4) (516) 1,963 Net Income 10,228 (908) (350) 129 259 (870) 11,098 Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 10,217 (908) (350) 129 259 (870) 11,087 Earnings per Common Share Assuming Dilution 4.02 $ (0.35) (0.14) 0.05 0.10 (0.34) 4.36 $ Tax Rate 12.4% 15.0% Only the line items that are affected by non-GAAP adjustments are shown. The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non- GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi- Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities MERCK & CO., INC., RAHWAY, N.J., USA THREE AND SIX MONTHS ENDED JUNE 30, 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b Non-GAAP Certain Other Items Adjustment Subtotal -- 5 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2025 2024 2Q June YTD 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,529 $15,806 $31,335 $15,775 $16,112 $31,887 $16,657 $15,624 $64,168 -2 -2 -2 0 PHARMACEUTICAL 13,638 14,050 27,688 14,006 14,408 28,415 14,943 14,042 57,400 -2 -3 -3 -2 Oncology Keytruda 7,205 7,956 15,161 6,947 7,270 14,217 7,429 7,836 29,482 9 9 7 8 Alliance Revenue – Lynparza (2) 312 370 682 292 317 609 337 365 1,311 17 15 12 12 Alliance Revenue – Lenvima (2) 258 265 523 255 249 504 251 255 1,010 6 5 4 4 Welireg 137 162 300 85 126 211 139 160 509 29 29 42 43 Alliance Revenue – Reblozyl (3) 119 107 226 71 90 161 100 110 371 19 19 40 40 Vaccines (4) Gardasil/Gardasil 9 1,327 1,126 2,453 2,249 2,478 4,727 2,306 1,550 8,583 -55 -55 -48 -48 ProQuad/M-M-R II/Varivax 539 609 1,148 570 617 1,187 703 594 2,485 -1 -2 -3 -3 Vaxneuvance 230 229 459 219 189 408 239 161 808 21 20 13 13 RotaTeq 228 121 349 216 163 379 193 139 711 -26 -26 -8 -7 Capvaxive 107 129 236 47 50 97 - - - - Pneumovax 23 41 38 79 61 59 120 68 74 263 -36 -37 -35 -33 Hospital Acute Care Bridion 441 461 902 440 455 895 420 449 1,764 1 1 1 1 Prevymis 208 228 436 174 188 362 208 215 785 21 20 20 21 Dificid 83 96 179 73 92 165 96 79 340 5 5 8 9 Zerbaxa 70 74 145 56 62 118 64 70 252 21 21 23 24 Cardiovascular Winrevair 280 336 615 70 70 149 200 419 * * * * Alliance Revenue - Adempas/Verquvo (5) 106 123 229 98 106 203 102 109 415 16 16 12 12 Adempas (6) 68 80 147 70 72 142 72 73 287 10 6 4 4 Virology Lagevrio 102 83 185 350 110 460 383 121 964 -25 -27 -60 -59 Isentress/Isentress HD 90 86 176 111 89 200 102 92 394 -3 -4 -12 -11 Delstrigo 67 83 150 56 60 116 65 69 249 40 35 30 30 Pifeltro 45 41 86 42 39 81 42 40 163 5 4 6 6 Neuroscience Belsomra 50 40 90 46 53 99 78 45 222 -24 -26 -9 -8 Immunology Simponi 184 172 356 189 543 -100 -100 -100 -100 Remicade 39 35 74 41 114 -100 -100 -100 -100 Diabetes (7) Januvia 549 372 921 419 405 824 278 232 1,334 -8 -8 12 13 Janumet 247 251 498 251 224 475 204 255 935 12 14 5 8 Other Pharmaceutical (8) 729 584 1,313 632 618 1,252 638 699 2,590 -6 -7 5 6 ANIMAL HEALTH 1,588 1,646 3,234 1,511 1,482 2,993 1,487 1,397 5,877 11 11 8 11 Livestock 924 961 1,885 850 837 1,686 886 889 3,462 15 16 12 16 Companion Animal 664 685 1,349 661 645 1,307 601 508 2,415 6 6 3 4 Other Revenues (9) 303 110 413 258 222 479 227 185 891 -50 -3 -14 7 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $876 million and $704 million in the first and second quarter of 2025, respectively, and $745 million and $715 million in the first and second quarter of 2024. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $95 million and $5 million in the first and second quarter of 2025, respectively, and $61 million and $15 million in the first and second quarter of 2024, respectively. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,607 million and $2,370 million in the first and second quarter of 2025, respectively, and $3,424 million and $3,656 million in the first and second quarter of 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in the Company's marketing territories. -- 6 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES SECOND QUARTER 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 2Q 2025 2Q 2024 % Change 2Q 2025 2Q 2024 % Change 2Q 2025 2Q 2024 % Change TOTAL SALES (1) $15,806 $16,112 -2 $8,836 $7,876 12 $6,969 $8,236 -15 PHARMACEUTICAL 14,050 14,408 -2 8,328 7,399 13 5,722 7,009 -18 Oncology Keytruda 7,956 7,270 9 4,749 4,412 8 3,207 2,858 12 Alliance Revenue – Lynparza (2) 370 317 17 174 153 14 195 165 19 Alliance Revenue – Lenvima (2) 265 249 6 183 177 3 83 73 14 Welireg 162 126 29 138 116 19 24 10 155 Alliance Revenue – Reblozyl (3) 107 90 19 88 75 18 19 15 24 Vaccines (4) Gardasil/Gardasil 9 1,126 2,478 -55 545 536 2 581 1,941 -70 ProQuad/M-M-R II/Varivax 609 617 -1 481 490 -2 128 127 1 Vaxneuvance 229 189 21 136 99 38 93 90 3 Capvaxive 129 - 129 - RotaTeq 121 163 -26 60 107 -44 61 56 9 Pneumovax 23 38 59 -36 5 11 -57 33 48 -31 Hospital Acute Care Bridion 461 455 1 411 351 17 50 104 -52 Prevymis 228 188 21 115 90 27 113 98 16 Dificid 96 92 5 83 79 4 13 12 8 Zerbaxa 74 62 21 45 33 35 29 28 5 Cardiovascular Winrevair 336 70 * 323 70 * 12 - Alliance Revenue - Adempas/Verquvo (5) 123 106 16 108 98 10 15 8 89 Adempas (6) 80 72 10 80 72 10 Virology Isentress/Isentress HD 86 89 -3 48 43 13 38 46 -18 Delstrigo 83 60 40 14 14 -5 70 45 55 Lagevrio 83 110 -25 30 15 103 52 95 -45 Pifeltro 41 39 5 25 27 -4 16 12 26 Neuroscience Belsomra 40 53 -24 18 19 -1 21 34 -37 Immunology Simponi 172 -100 172 -100 Remicade 35 -100 35 -100 Diabetes (7) Januvia 372 405 -8 216 177 22 155 227 -32 Janumet 251 224 12 68 17 * 184 208 -12 Other Pharmaceutical (8) 584 618 -6 136 190 -28 450 430 5 ANIMAL HEALTH 1,646 1,482 11 499 455 9 1,147 1,027 12 Livestock 961 837 15 190 168 13 771 669 15 Companion Animal 685 645 6 309 287 8 376 358 5 Other Revenues (9) 110 222 -50 9 22 -59 100 200 -50 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $704 million and $715 million on a global basis in the second quarter of 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $5 million and $15 million in the second quarter of 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $2,370 million and $3,656 million on a global basis in the second quarter of 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. -- 7 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA FRANCHISE / KEY PRODUCT SALES JUNE YEAR-TO-DATE 2025 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International June YTD 2025 June YTD 2024 % Change June YTD 2025 June YTD 2024 % Change June YTD 2025 June YTD 2024 % Change TOTAL SALES (1) $31,335 $31,887 -2 $17,359 $15,354 13 $13,977 $16,533 -15 PHARMACEUTICAL 27,688 28,415 -3 16,254 14,336 13 11,434 14,079 -19 Oncology Keytruda 15,161 14,217 7 9,057 8,531 6 6,104 5,686 7 Alliance Revenue – Lynparza (2) 682 609 12 319 288 11 363 321 13 Alliance Revenue – Lenvima (2) 523 504 4 368 349 5 155 155 - Welireg 300 211 42 261 194 35 39 17 130 Alliance Revenue – Reblozyl (3) 226 161 40 189 133 42 37 28 34 Vaccines (4) Gardasil/Gardasil 9 2,453 4,727 -48 1,082 1,024 6 1,371 3,702 -63 ProQuad/M-M-R II/Varivax 1,148 1,187 -3 903 928 -3 245 259 -6 Vaxneuvance 459 408 13 275 260 6 184 148 25 RotaTeq 349 379 -8 225 257 -12 125 123 2 Capvaxive 236 - 235 - 1 - Pneumovax 23 79 120 -35 3 17 -82 76 103 -27 Hospital Acute Care Bridion 902 895 1 789 680 16 113 215 -47 Prevymis 436 362 20 217 165 32 219 197 11 Dificid 179 165 8 155 147 5 24 17 39 Zerbaxa 145 118 23 87 67 31 57 51 12 Cardiovascular Winrevair 615 70 * 591 70 * 24 - Alliance Revenue - Adempas/Verquvo (5) 229 203 12 205 188 9 23 16 50 Adempas (6) 147 142 4 147 142 4 Virology Lagevrio 185 460 -60 66 60 10 119 400 -70 Isentress/Isentress HD 176 200 -12 99 93 7 77 107 -28 Delstrigo 150 116 30 29 26 10 121 89 36 Pifeltro 86 81 6 57 56 2 29 25 14 Neuroscience Belsomra 90 99 -9 31 33 -5 58 66 -12 Immunology Simponi 356 -100 356 -100 Remicade 74 -100 74 -100 Diabetes (7) Januvia 921 824 12 561 361 55 360 463 -22 Janumet 498 475 5 133 55 140 366 420 -13 Other Pharmaceutical (8) 1,313 1,252 5 317 354 -10 997 899 11 ANIMAL HEALTH 3,234 2,993 8 1,001 929 8 2,233 2,064 8 Livestock 1,885 1,686 12 384 334 15 1,501 1,352 11 Companion Animal 1,349 1,307 3 617 595 4 732 712 3 Other Revenues (9) 413 479 -14 104 89 17 310 390 -21 *200% or greater (6) Net product sales in the Company's marketing territories. (7) Total Diabetes sales were $1,580 million and $1,461 million on a global basis for June YTD 2025 and 2024, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $100 million and $76 million on a global basis for June YTD 2025 and 2024, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $4,977 million and $7,080 million on a global basis for June YTD 2025 and 2024, respectively. (5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. -- 8 of 10 -- MERCK & CO., INC., RAHWAY, N.J., USA PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2025 2024 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD TOTAL PHARMACEUTICAL $13,638 $14,050 $27,688 $14,006 $14,408 $28,415 $14,943 $14,042 $57,400 -2 -3 United States 7,927 8,328 16,254 6,936 7,399 14,336 8,227 7,728 30,290 13 13 % Pharmaceutical Sales 58.1% 59.3% 58.7% 49.5% 51.4% 50.5% 55.1% 55.0% 52.8% Europe (1) 2,384 2,551 4,935 2,555 2,572 5,128 2,620 2,498 10,246 -1 -4 % Pharmaceutical Sales 17.5% 18.2% 17.8% 18.2% 17.9% 18.0% 17.5% 17.8% 17.9% Japan 651 604 1,255 802 664 1,466 919 813 3,199 -9 -14 % Pharmaceutical Sales 4.8% 4.3% 4.5% 5.7% 4.6% 5.2% 6.2% 5.8% 5.6% Latin America 589 654 1,243 601 661 1,262 730 680 2,672 -1 -2 % Pharmaceutical Sales 4.3% 4.7% 4.5% 4.3% 4.6% 4.4% 4.9% 4.8% 4.7% Asia Pacific (other than China and Japan) 535 609 1,144 580 595 1,175 669 612 2,457 2 -3 % Pharmaceutical Sales 3.9% 4.3% 4.1% 4.1% 4.1% 4.1% 4.5% 4.4% 4.3% China (2) 668 407 1,075 1,744 1,790 3,534 996 864 5,394 -77 -70 % Pharmaceutical Sales 4.9% 2.9% 3.9% 12.5% 12.4% 12.4% 6.7% 6.2% 9.4% Eastern Europe/Middle East/Africa 435 451 886 395 353 747 400 348 1,495 28 19 % Pharmaceutical Sales 3.2% 3.2% 3.2% 2.8% 2.4% 2.6% 2.7% 2.5% 2.6% Canada 125 135 261 138 143 281 133 144 558 -6 -7 % Pharmaceutical Sales 0.9% 1.0% 0.9% 1.0% 1.0% 1.0% 0.9% 1.0% 1.0% Other 324 311 635 255 231 486 249 355 1,089 35 31 % Pharmaceutical Sales 2.4% 2.1% 2.4% 1.9% 1.6% 1.8% 1.5% 2.5% 1.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. (2) Gardasil/Gardasil 9 sales in China were $193 million and $0 in the first and second quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first, second, third and fourth quarter of 2024, respectively. -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 2Q25 2Q24 June YTD 2025 June YTD 2024 Interest income (69) $ (69) $ (178) $ (141) $ Interest expense 305 310 618 613 Exchange losses 78 60 167 144 Income from investments in equity securities, net (1) (100) (56) (189) (200) Net periodic defined benefit plan (credit) cost other than service cost (152) (159) (300) (319) Other, net (69) (44) (161) (85) Total (7) $ 42 $ (43) $ 12 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC., RAHWAY, N.J., USA OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 -- 10 of 10 --